Cosmo’s Rifamycin Gel Meets Phase 2 Remission Endpoint
Cosmo reported remission in 46.2% of patients versus 14.3% on placebo (p=0.0190). It plans FDA and EMA discussions and to advance toward Phase 3.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.